Showing 6501-6510 of 8286 results for "".
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://practicaldermatology.com/news/researchers-define-keys-to-recognizing-ocular-rosacea-1/2461052/A number of eye symptoms may be more common in patients with rosacea compared to those without the skin disease, but the presence of conjunctival telangiectases may be the eye symptom most closely associated with rosacea. Findings come from a study in which researchers evaluated the rig
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results
- Is CBG the Next CBD for Skincare?https://practicaldermatology.com/news/is-cbg-the-next-cbd-for-skincare/2461042/Cannabigerol (CBG) shows antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays and provides similar benefits when applied topically to human skin, according to new research. In a single-blind c
- DecisionDx-SCC Performs Well as a Risk-Stratification Tool in Patients with High-risk SCChttps://practicaldermatology.com/news/decisiondx-scc-performs-well-as-a-risk-stratification-tool-in-patients-with-high-risk-scc/2461039/Castle Biosciences, Inc’s DecisionDx-SCC can provide significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk), a new study shows. The study appears in&nb
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Vial Launches Dermatology CROhttps://practicaldermatology.com/news/vial-launches-dermatology-cro/2461031/Vial has launched the Vial Dermatology CRO, dubbing it “The CRO Built for Sponsors.” The San Francisco-based company will rely on a clinic network of more than 35 dermatology clinics across the country to re
- Cybersecurity Firm Offers Tips to Protect Dermatology Practice Datahttps://practicaldermatology.com/news/cybersecurity-firm-offers-tips-to-protect-dermatology-practice-data/2461029/Ransomware attacks continue to target the healthcare sector. Black Talon Security, a leading NY-based national cybersecurity firm, offers 10 tips that all dermatology practices should follow to keep data secure and protect patient r
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p